Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
Not Applicable
Completed
- Conditions
- Systemic Lupus ErythematosusAntiphospholipid Antibody Syndrome
- Registration Number
- NCT00010400
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
OBJECTIVES:
I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide.
II. Determine the toxicity of this drug in these patients.
- Detailed Description
PROTOCOL OUTLINE:
Patients receive cyclophosphamide IV on days 1-4 and filgrastim (G-CSF) beginning on day 10 and continuing until blood counts recover.
Patients are followed monthly for 6 months, and then every 3 months thereafter.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Johns Hopkins University School of Medicine
🇺🇸Baltimore, Maryland, United States
Johns Hopkins Oncology Center
🇺🇸Baltimore, Maryland, United States
Johns Hopkins University School of Medicine🇺🇸Baltimore, Maryland, United States